Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 155 | 2024 | 5315 | 9.840 |
Why?
|
Lung Neoplasms | 223 | 2024 | 13380 | 9.740 |
Why?
|
Protein Kinase Inhibitors | 82 | 2024 | 5671 | 4.840 |
Why?
|
Quinazolines | 42 | 2018 | 1371 | 4.390 |
Why?
|
Acrylamides | 20 | 2024 | 260 | 3.590 |
Why?
|
Drug Resistance, Neoplasm | 47 | 2023 | 5305 | 2.970 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 48 | 2024 | 11742 | 2.500 |
Why?
|
Antineoplastic Agents | 66 | 2024 | 13639 | 2.430 |
Why?
|
Mutation | 113 | 2024 | 30052 | 2.360 |
Why?
|
Adenocarcinoma | 31 | 2018 | 6346 | 2.110 |
Why?
|
Early Detection of Cancer | 19 | 2024 | 3201 | 2.040 |
Why?
|
Small Cell Lung Carcinoma | 10 | 2021 | 423 | 1.880 |
Why?
|
Neoplastic Cells, Circulating | 24 | 2018 | 946 | 1.780 |
Why?
|
Genes, erbB-1 | 12 | 2018 | 162 | 1.510 |
Why?
|
Aniline Compounds | 18 | 2024 | 1069 | 1.500 |
Why?
|
Protein-Tyrosine Kinases | 13 | 2021 | 2425 | 1.500 |
Why?
|
Pyrimidines | 13 | 2024 | 3028 | 1.160 |
Why?
|
HSP90 Heat-Shock Proteins | 5 | 2018 | 424 | 1.070 |
Why?
|
Proto-Oncogene Proteins c-met | 10 | 2021 | 571 | 0.920 |
Why?
|
Gene Amplification | 9 | 2020 | 1089 | 0.880 |
Why?
|
Neoplasm Staging | 31 | 2024 | 11121 | 0.790 |
Why?
|
Resorcinols | 2 | 2018 | 41 | 0.780 |
Why?
|
Molecular Targeted Therapy | 18 | 2023 | 2811 | 0.770 |
Why?
|
Cell Separation | 10 | 2017 | 1720 | 0.750 |
Why?
|
Proto-Oncogene Proteins c-ret | 3 | 2020 | 225 | 0.740 |
Why?
|
Quinolines | 6 | 2018 | 764 | 0.730 |
Why?
|
Humans | 264 | 2024 | 761504 | 0.710 |
Why?
|
Aged, 80 and over | 67 | 2024 | 58976 | 0.710 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 11 | 2023 | 1745 | 0.700 |
Why?
|
Piperazines | 7 | 2019 | 2523 | 0.690 |
Why?
|
Isoxazoles | 2 | 2018 | 232 | 0.690 |
Why?
|
Pyrrolidinones | 4 | 2018 | 116 | 0.640 |
Why?
|
Neuregulin-1 | 1 | 2019 | 135 | 0.610 |
Why?
|
Guanine | 7 | 2015 | 279 | 0.610 |
Why?
|
Glutamates | 7 | 2015 | 389 | 0.610 |
Why?
|
Neoplasm Metastasis | 17 | 2022 | 4915 | 0.600 |
Why?
|
Aged | 102 | 2024 | 169289 | 0.590 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2012 | 774 | 0.570 |
Why?
|
Mutagenesis, Insertional | 3 | 2018 | 656 | 0.570 |
Why?
|
Proto-Oncogene Proteins | 11 | 2021 | 4511 | 0.560 |
Why?
|
Salvage Therapy | 5 | 2020 | 1264 | 0.560 |
Why?
|
Middle Aged | 107 | 2024 | 220895 | 0.560 |
Why?
|
DNA Mutational Analysis | 16 | 2018 | 4111 | 0.550 |
Why?
|
Female | 144 | 2024 | 392644 | 0.550 |
Why?
|
Male | 136 | 2024 | 360804 | 0.550 |
Why?
|
Receptor Protein-Tyrosine Kinases | 13 | 2022 | 1626 | 0.540 |
Why?
|
Survival Rate | 24 | 2021 | 12725 | 0.530 |
Why?
|
Carboplatin | 6 | 2020 | 794 | 0.510 |
Why?
|
Microfluidics | 5 | 2018 | 653 | 0.510 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2020 | 9280 | 0.500 |
Why?
|
Histone Deacetylases | 2 | 2010 | 719 | 0.500 |
Why?
|
Carcinoma, Small Cell | 1 | 2017 | 420 | 0.490 |
Why?
|
Genotype | 17 | 2017 | 12990 | 0.490 |
Why?
|
Lactams, Macrocyclic | 3 | 2017 | 318 | 0.470 |
Why?
|
Disease-Free Survival | 14 | 2018 | 6814 | 0.470 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 350 | 0.470 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2019 | 2057 | 0.460 |
Why?
|
Brain Neoplasms | 10 | 2022 | 9031 | 0.440 |
Why?
|
Exons | 8 | 2021 | 2391 | 0.440 |
Why?
|
Biopsy | 8 | 2021 | 6766 | 0.420 |
Why?
|
Prognosis | 28 | 2020 | 29625 | 0.410 |
Why?
|
Adult | 76 | 2024 | 221177 | 0.410 |
Why?
|
Pyrazoles | 11 | 2021 | 2009 | 0.410 |
Why?
|
Gene Rearrangement | 6 | 2019 | 1125 | 0.410 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2021 | 8547 | 0.410 |
Why?
|
Cisplatin | 9 | 2018 | 1651 | 0.400 |
Why?
|
Hydroxychloroquine | 2 | 2015 | 426 | 0.400 |
Why?
|
Treatment Outcome | 42 | 2021 | 64680 | 0.400 |
Why?
|
Triazines | 3 | 2024 | 311 | 0.390 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2020 | 4026 | 0.380 |
Why?
|
Oncogene Proteins, Fusion | 6 | 2021 | 1606 | 0.380 |
Why?
|
Cell Line, Tumor | 31 | 2021 | 16981 | 0.360 |
Why?
|
Mass Screening | 6 | 2024 | 5428 | 0.360 |
Why?
|
Tomography, X-Ray Computed | 14 | 2023 | 20570 | 0.350 |
Why?
|
Benzoquinones | 1 | 2010 | 198 | 0.340 |
Why?
|
Epithelial-Mesenchymal Transition | 5 | 2019 | 736 | 0.340 |
Why?
|
Patient Selection | 6 | 2019 | 4244 | 0.340 |
Why?
|
Microfluidic Analytical Techniques | 6 | 2017 | 803 | 0.340 |
Why?
|
Radiosurgery | 2 | 2016 | 1342 | 0.330 |
Why?
|
RNA, Neoplasm | 5 | 2018 | 750 | 0.310 |
Why?
|
Receptor, IGF Type 1 | 1 | 2010 | 379 | 0.300 |
Why?
|
Pyridines | 10 | 2022 | 2875 | 0.300 |
Why?
|
Antibodies, Monoclonal | 5 | 2018 | 9177 | 0.280 |
Why?
|
Glutathione | 1 | 2009 | 583 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 13 | 2020 | 6484 | 0.280 |
Why?
|
Diagnostic Tests, Routine | 2 | 2011 | 787 | 0.280 |
Why?
|
Survival Analysis | 14 | 2019 | 10090 | 0.280 |
Why?
|
DNA, Neoplasm | 6 | 2016 | 1745 | 0.280 |
Why?
|
Follow-Up Studies | 16 | 2020 | 39106 | 0.270 |
Why?
|
Point Mutation | 2 | 2011 | 1595 | 0.260 |
Why?
|
Heat-Shock Proteins | 1 | 2009 | 795 | 0.250 |
Why?
|
Hedgehog Proteins | 1 | 2010 | 768 | 0.250 |
Why?
|
Cohort Studies | 20 | 2024 | 41487 | 0.250 |
Why?
|
Sirolimus | 1 | 2012 | 1533 | 0.250 |
Why?
|
In Situ Hybridization, Fluorescence | 8 | 2012 | 2510 | 0.250 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2019 | 257 | 0.250 |
Why?
|
Disease Progression | 14 | 2021 | 13506 | 0.250 |
Why?
|
ras Proteins | 5 | 2014 | 1054 | 0.250 |
Why?
|
Molecular Chaperones | 1 | 2009 | 754 | 0.240 |
Why?
|
Lactams | 3 | 2021 | 156 | 0.240 |
Why?
|
Paclitaxel | 3 | 2018 | 1732 | 0.240 |
Why?
|
Clinical Trials as Topic | 11 | 2020 | 8002 | 0.230 |
Why?
|
Blood Chemical Analysis | 2 | 2024 | 437 | 0.230 |
Why?
|
Lung | 9 | 2023 | 10000 | 0.220 |
Why?
|
Deoxycytidine | 5 | 2018 | 877 | 0.220 |
Why?
|
Eligibility Determination | 2 | 2024 | 421 | 0.220 |
Why?
|
RNA | 5 | 2018 | 2726 | 0.210 |
Why?
|
Radiopharmaceuticals | 2 | 2015 | 2651 | 0.200 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 2010 | 0.200 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 883 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2018 | 10766 | 0.200 |
Why?
|
Retrospective Studies | 27 | 2021 | 80636 | 0.200 |
Why?
|
Xenograft Model Antitumor Assays | 10 | 2019 | 3602 | 0.200 |
Why?
|
Receptors, Androgen | 4 | 2018 | 1079 | 0.190 |
Why?
|
Aminopyridines | 3 | 2021 | 573 | 0.190 |
Why?
|
Hepatocyte Growth Factor | 2 | 2021 | 270 | 0.190 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 243 | 0.190 |
Why?
|
Receptors, Growth Factor | 3 | 2011 | 326 | 0.190 |
Why?
|
Mosaicism | 1 | 2024 | 475 | 0.190 |
Why?
|
Genetic Testing | 3 | 2009 | 3537 | 0.190 |
Why?
|
Prospective Studies | 14 | 2024 | 54425 | 0.180 |
Why?
|
Organoplatinum Compounds | 4 | 2018 | 407 | 0.180 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2024 | 592 | 0.180 |
Why?
|
Forecasting | 3 | 2023 | 2928 | 0.180 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2024 | 339 | 0.170 |
Why?
|
Nanostructures | 2 | 2015 | 553 | 0.170 |
Why?
|
Wnt Proteins | 2 | 2015 | 718 | 0.170 |
Why?
|
Benzimidazoles | 3 | 2022 | 858 | 0.170 |
Why?
|
Hand Strength | 1 | 2023 | 456 | 0.170 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2022 | 173 | 0.170 |
Why?
|
Carbazoles | 2 | 2021 | 220 | 0.160 |
Why?
|
Drug Administration Schedule | 5 | 2018 | 4853 | 0.160 |
Why?
|
Pyrimidinones | 2 | 2019 | 385 | 0.160 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2529 | 0.160 |
Why?
|
Nicotine | 2 | 2022 | 680 | 0.160 |
Why?
|
Education, Nursing, Continuing | 1 | 2018 | 70 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
Receptor, erbB-3 | 1 | 2019 | 143 | 0.150 |
Why?
|
Retreatment | 2 | 2019 | 598 | 0.150 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2917 | 0.150 |
Why?
|
Signal Transduction | 12 | 2021 | 23445 | 0.150 |
Why?
|
Neoplasms | 8 | 2024 | 22170 | 0.150 |
Why?
|
Remission Induction | 2 | 2016 | 2396 | 0.150 |
Why?
|
Geriatric Assessment | 1 | 2005 | 1410 | 0.140 |
Why?
|
Enzyme Inhibitors | 3 | 2013 | 3712 | 0.140 |
Why?
|
Combined Modality Therapy | 5 | 2016 | 8529 | 0.140 |
Why?
|
Platinum Compounds | 2 | 2019 | 95 | 0.140 |
Why?
|
MAP Kinase Kinase 1 | 3 | 2014 | 332 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 3617 | 0.140 |
Why?
|
Tissue Distribution | 3 | 2020 | 2265 | 0.140 |
Why?
|
Piperidines | 3 | 2021 | 1656 | 0.140 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 899 | 0.140 |
Why?
|
Artificial Intelligence | 4 | 2024 | 2578 | 0.140 |
Why?
|
Biopsy, Fine-Needle | 2 | 2019 | 1118 | 0.130 |
Why?
|
beta-Globins | 1 | 2017 | 111 | 0.130 |
Why?
|
Androstenes | 1 | 2018 | 181 | 0.130 |
Why?
|
Mice, Nude | 6 | 2019 | 3615 | 0.130 |
Why?
|
Pyridones | 2 | 2019 | 809 | 0.130 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2019 | 278 | 0.130 |
Why?
|
Lab-On-A-Chip Devices | 2 | 2017 | 432 | 0.130 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2016 | 191 | 0.130 |
Why?
|
Indoles | 1 | 2024 | 1833 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2024 | 10209 | 0.130 |
Why?
|
Health Services Needs and Demand | 1 | 2023 | 1403 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 641 | 0.130 |
Why?
|
Blood Cells | 1 | 2017 | 305 | 0.130 |
Why?
|
North America | 1 | 2018 | 1276 | 0.120 |
Why?
|
Osteopontin | 1 | 2017 | 301 | 0.120 |
Why?
|
Genetic Heterogeneity | 2 | 2016 | 732 | 0.120 |
Why?
|
Norepinephrine | 1 | 2017 | 897 | 0.120 |
Why?
|
Thoracic Neoplasms | 1 | 2017 | 267 | 0.120 |
Why?
|
Alleles | 3 | 2021 | 6863 | 0.120 |
Why?
|
Th1 Cells | 1 | 2019 | 1036 | 0.120 |
Why?
|
Pilot Projects | 5 | 2017 | 8631 | 0.120 |
Why?
|
High-Throughput Screening Assays | 2 | 2017 | 934 | 0.120 |
Why?
|
Benzamides | 4 | 2024 | 1370 | 0.120 |
Why?
|
Smoking | 2 | 2024 | 9053 | 0.120 |
Why?
|
Scleroderma, Localized | 1 | 2015 | 87 | 0.120 |
Why?
|
Pain, Intractable | 1 | 2015 | 132 | 0.120 |
Why?
|
Epinephrine | 1 | 2017 | 792 | 0.110 |
Why?
|
Cell Survival | 7 | 2019 | 5791 | 0.110 |
Why?
|
Pyrazines | 1 | 2020 | 1201 | 0.110 |
Why?
|
United States | 6 | 2024 | 72334 | 0.110 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 258 | 0.110 |
Why?
|
Phenylthiohydantoin | 1 | 2015 | 205 | 0.110 |
Why?
|
Alginates | 1 | 2015 | 248 | 0.110 |
Why?
|
Biological Specimen Banks | 1 | 2019 | 783 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3514 | 0.110 |
Why?
|
Prostaglandins | 1 | 2014 | 398 | 0.110 |
Why?
|
Tumor Burden | 2 | 2018 | 1893 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.110 |
Why?
|
Puerperal Disorders | 1 | 2016 | 299 | 0.110 |
Why?
|
Young Adult | 13 | 2021 | 59243 | 0.110 |
Why?
|
Informed Consent | 1 | 2019 | 1008 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4575 | 0.100 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1342 | 0.100 |
Why?
|
RNA, Messenger | 3 | 2017 | 12795 | 0.100 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 11903 | 0.100 |
Why?
|
Patient Preference | 1 | 2019 | 924 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2017 | 1241 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 2047 | 0.100 |
Why?
|
Double-Blind Method | 4 | 2020 | 12341 | 0.100 |
Why?
|
Recombination, Genetic | 2 | 2013 | 1519 | 0.100 |
Why?
|
Neovascularization, Pathologic | 2 | 2015 | 2645 | 0.100 |
Why?
|
Immunohistochemistry | 3 | 2014 | 11076 | 0.090 |
Why?
|
Retinoblastoma Protein | 1 | 2015 | 672 | 0.090 |
Why?
|
Sex Factors | 2 | 2023 | 10552 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2019 | 3162 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1801 | 0.090 |
Why?
|
Glioblastoma | 2 | 2018 | 3482 | 0.090 |
Why?
|
Carcinoma, Large Cell | 2 | 2008 | 113 | 0.090 |
Why?
|
Fanconi Anemia | 1 | 2013 | 324 | 0.090 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2008 | 89 | 0.090 |
Why?
|
Conscious Sedation | 1 | 2015 | 532 | 0.090 |
Why?
|
Sequence Analysis, RNA | 5 | 2017 | 2020 | 0.090 |
Why?
|
Tumor Cells, Cultured | 5 | 2019 | 6132 | 0.090 |
Why?
|
Translocation, Genetic | 1 | 2016 | 1393 | 0.090 |
Why?
|
Research Design | 4 | 2020 | 6180 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2021 | 3492 | 0.090 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3877 | 0.090 |
Why?
|
Melanoma | 2 | 2019 | 5709 | 0.090 |
Why?
|
Biocompatible Materials | 2 | 2015 | 1685 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2012 | 410 | 0.090 |
Why?
|
Cell Proliferation | 4 | 2020 | 10445 | 0.080 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 517 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 6 | 2024 | 17904 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2013 | 12059 | 0.080 |
Why?
|
Prostatic Neoplasms | 6 | 2017 | 11118 | 0.080 |
Why?
|
International Agencies | 1 | 2010 | 243 | 0.080 |
Why?
|
Depression | 3 | 2017 | 8124 | 0.080 |
Why?
|
Nomograms | 1 | 2011 | 230 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2013 | 12463 | 0.080 |
Why?
|
Drug Delivery Systems | 2 | 2012 | 2226 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1897 | 0.080 |
Why?
|
Retinal Diseases | 1 | 2015 | 705 | 0.080 |
Why?
|
Cytotoxins | 1 | 2009 | 153 | 0.080 |
Why?
|
Central Nervous System | 1 | 2016 | 1336 | 0.080 |
Why?
|
Mice | 16 | 2019 | 81525 | 0.080 |
Why?
|
Immunotherapy | 3 | 2021 | 4652 | 0.080 |
Why?
|
Genes, ras | 2 | 2011 | 654 | 0.080 |
Why?
|
Predictive Value of Tests | 6 | 2019 | 15266 | 0.080 |
Why?
|
Endpoint Determination | 1 | 2011 | 590 | 0.080 |
Why?
|
Animals | 21 | 2019 | 168459 | 0.080 |
Why?
|
Genetic Markers | 2 | 2012 | 2601 | 0.080 |
Why?
|
Time Factors | 6 | 2021 | 39967 | 0.080 |
Why?
|
Analgesics | 1 | 2015 | 1070 | 0.080 |
Why?
|
Amino Acid Substitution | 3 | 2021 | 1738 | 0.070 |
Why?
|
Drug Synergism | 1 | 2012 | 1755 | 0.070 |
Why?
|
Triazoles | 1 | 2013 | 903 | 0.070 |
Why?
|
Phenotype | 2 | 2018 | 16591 | 0.070 |
Why?
|
Injections, Intravenous | 1 | 2009 | 1379 | 0.070 |
Why?
|
Medical Oncology | 3 | 2024 | 2321 | 0.070 |
Why?
|
Oncogenes | 3 | 2021 | 1222 | 0.070 |
Why?
|
Placebos | 1 | 2011 | 1667 | 0.070 |
Why?
|
Genome, Human | 1 | 2020 | 4425 | 0.070 |
Why?
|
Aminoquinolines | 1 | 2007 | 107 | 0.070 |
Why?
|
Sequence Deletion | 2 | 2008 | 1494 | 0.070 |
Why?
|
Blood Platelets | 1 | 2017 | 2479 | 0.070 |
Why?
|
Fractures, Compression | 1 | 2008 | 131 | 0.070 |
Why?
|
Sulfonamides | 4 | 2018 | 1978 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 611 | 0.070 |
Why?
|
Androgen Antagonists | 1 | 2015 | 1410 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2020 | 9000 | 0.070 |
Why?
|
Imidazoles | 2 | 2024 | 1180 | 0.070 |
Why?
|
Apoptosis | 6 | 2019 | 9486 | 0.070 |
Why?
|
Hyperglycemia | 1 | 2015 | 1376 | 0.070 |
Why?
|
Receptor, erbB-2 | 3 | 2014 | 2557 | 0.070 |
Why?
|
Mutation, Missense | 2 | 2013 | 2571 | 0.070 |
Why?
|
Organic Chemicals | 1 | 2007 | 210 | 0.070 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2011 | 1135 | 0.070 |
Why?
|
Cell Growth Processes | 2 | 2019 | 384 | 0.060 |
Why?
|
Antirheumatic Agents | 1 | 2015 | 1372 | 0.060 |
Why?
|
Membrane Proteins | 2 | 2013 | 7856 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 1993 | 0.060 |
Why?
|
Radiography | 3 | 2015 | 6965 | 0.060 |
Why?
|
Microarray Analysis | 1 | 2007 | 749 | 0.060 |
Why?
|
Staining and Labeling | 1 | 2009 | 1085 | 0.060 |
Why?
|
Terminal Care | 1 | 2016 | 1760 | 0.060 |
Why?
|
Back Pain | 1 | 2008 | 545 | 0.060 |
Why?
|
Retina | 1 | 2015 | 2659 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 2298 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6310 | 0.060 |
Why?
|
Phthalazines | 2 | 2019 | 383 | 0.060 |
Why?
|
Thoracic Vertebrae | 1 | 2008 | 597 | 0.060 |
Why?
|
Morpholines | 1 | 2007 | 581 | 0.060 |
Why?
|
Pharmacogenetics | 1 | 2008 | 675 | 0.060 |
Why?
|
Radiotherapy | 1 | 2010 | 1499 | 0.050 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2007 | 517 | 0.050 |
Why?
|
ROC Curve | 1 | 2011 | 3579 | 0.050 |
Why?
|
Mice, SCID | 2 | 2018 | 2626 | 0.050 |
Why?
|
Sulfones | 2 | 2016 | 448 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9469 | 0.050 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 2 | 2013 | 146 | 0.050 |
Why?
|
Rad51 Recombinase | 2 | 2013 | 189 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2024 | 297 | 0.050 |
Why?
|
Positron-Emission Tomography | 3 | 2018 | 6485 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2008 | 962 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5821 | 0.050 |
Why?
|
Consensus | 2 | 2022 | 3123 | 0.050 |
Why?
|
Gene Expression | 4 | 2017 | 7581 | 0.050 |
Why?
|
Breast Neoplasms | 4 | 2018 | 21012 | 0.050 |
Why?
|
Age Distribution | 1 | 2007 | 2880 | 0.050 |
Why?
|
Spinal Fractures | 1 | 2008 | 705 | 0.050 |
Why?
|
Quality of Life | 4 | 2018 | 13367 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 14666 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2898 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4320 | 0.050 |
Why?
|
History, 21st Century | 2 | 2017 | 1567 | 0.050 |
Why?
|
Models, Molecular | 3 | 2021 | 5439 | 0.040 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 317 | 0.040 |
Why?
|
Up-Regulation | 2 | 2021 | 4124 | 0.040 |
Why?
|
Platinum | 1 | 2021 | 220 | 0.040 |
Why?
|
Single-Cell Analysis | 3 | 2017 | 2449 | 0.040 |
Why?
|
Case-Control Studies | 4 | 2024 | 22176 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 2019 | 2141 | 0.040 |
Why?
|
Transforming Growth Factor beta | 2 | 2021 | 1961 | 0.040 |
Why?
|
Radiobiology | 1 | 2020 | 90 | 0.040 |
Why?
|
Palliative Care | 1 | 2015 | 3598 | 0.040 |
Why?
|
Cell Count | 2 | 2015 | 1835 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2008 | 916 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4174 | 0.040 |
Why?
|
Anilides | 1 | 2022 | 411 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2019 | 3429 | 0.040 |
Why?
|
Neurosurgical Procedures | 1 | 2010 | 2072 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 709 | 0.040 |
Why?
|
Transfection | 2 | 2020 | 5774 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.040 |
Why?
|
Diphenylamine | 1 | 2018 | 49 | 0.040 |
Why?
|
Solvents | 1 | 2020 | 295 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2019 | 117 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 612 | 0.040 |
Why?
|
Cell Cycle | 2 | 2017 | 2932 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5821 | 0.040 |
Why?
|
Entropy | 1 | 2019 | 210 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 38 | 0.040 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2019 | 242 | 0.040 |
Why?
|
Gene Dosage | 2 | 2016 | 1217 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74206 | 0.040 |
Why?
|
Disease Models, Animal | 4 | 2018 | 18252 | 0.040 |
Why?
|
Inflammation | 1 | 2017 | 10773 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 4021 | 0.040 |
Why?
|
Automation, Laboratory | 1 | 2017 | 102 | 0.040 |
Why?
|
Polymerase Chain Reaction | 3 | 2012 | 6075 | 0.030 |
Why?
|
Blood Preservation | 1 | 2017 | 168 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9420 | 0.030 |
Why?
|
Receptors, Adrenergic, beta | 1 | 2017 | 242 | 0.030 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2735 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 12974 | 0.030 |
Why?
|
Genetic Variation | 1 | 2012 | 6567 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2011 | 5796 | 0.030 |
Why?
|
Hyperphosphatemia | 1 | 2016 | 38 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2021 | 1435 | 0.030 |
Why?
|
DNA Damage | 2 | 2019 | 2446 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 2898 | 0.030 |
Why?
|
Cytoprotection | 1 | 2017 | 200 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2024 | 1858 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 3595 | 0.030 |
Why?
|
Tyrosine | 1 | 2020 | 1440 | 0.030 |
Why?
|
Models, Theoretical | 2 | 2020 | 3575 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2017 | 379 | 0.030 |
Why?
|
Hexuronic Acids | 1 | 2015 | 145 | 0.030 |
Why?
|
Glucuronic Acid | 1 | 2015 | 150 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2021 | 3076 | 0.030 |
Why?
|
Misonidazole | 1 | 2015 | 33 | 0.030 |
Why?
|
Nausea | 1 | 2018 | 679 | 0.030 |
Why?
|
DNA | 1 | 2009 | 7212 | 0.030 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 502 | 0.030 |
Why?
|
Peripartum Period | 1 | 2016 | 137 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2017 | 3639 | 0.030 |
Why?
|
Polyamines | 1 | 2015 | 133 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2017 | 479 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 5368 | 0.030 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 145 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2455 | 0.030 |
Why?
|
Republic of Korea | 1 | 2016 | 590 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 106 | 0.030 |
Why?
|
Platelet Activation | 1 | 2017 | 645 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 1640 | 0.030 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2017 | 504 | 0.030 |
Why?
|
Structural Homology, Protein | 1 | 2013 | 87 | 0.030 |
Why?
|
Immunoassay | 1 | 2017 | 745 | 0.030 |
Why?
|
Depressive Disorder, Major | 1 | 2011 | 4761 | 0.030 |
Why?
|
Age Factors | 2 | 2013 | 18395 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1827 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2014 | 2865 | 0.030 |
Why?
|
Proto-Oncogenes | 1 | 2014 | 321 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2469 | 0.030 |
Why?
|
bcl-X Protein | 1 | 2015 | 410 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 115 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2015 | 392 | 0.030 |
Why?
|
Exosomes | 1 | 2018 | 424 | 0.030 |
Why?
|
Electroretinography | 1 | 2015 | 525 | 0.030 |
Why?
|
Codon | 1 | 2015 | 601 | 0.030 |
Why?
|
Biological Transport | 1 | 2018 | 2091 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1334 | 0.030 |
Why?
|
Registries | 1 | 2009 | 8224 | 0.030 |
Why?
|
Gelatin | 1 | 2015 | 220 | 0.030 |
Why?
|
Dermatitis | 1 | 2015 | 202 | 0.030 |
Why?
|
Visual Field Tests | 1 | 2015 | 411 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2017 | 1202 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2017 | 1699 | 0.030 |
Why?
|
Wnt2 Protein | 1 | 2012 | 28 | 0.030 |
Why?
|
Contact Inhibition | 1 | 2012 | 46 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2015 | 656 | 0.030 |
Why?
|
Hepatitis B, Chronic | 1 | 2017 | 410 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2013 | 164 | 0.030 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 506 | 0.030 |
Why?
|
Surface Properties | 1 | 2015 | 1161 | 0.030 |
Why?
|
Cyclooxygenase 2 | 1 | 2014 | 597 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 465 | 0.020 |
Why?
|
Mitomycin | 1 | 2013 | 263 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2014 | 718 | 0.020 |
Why?
|
Exodeoxyribonucleases | 1 | 2013 | 192 | 0.020 |
Why?
|
Albumins | 1 | 2015 | 575 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2016 | 5247 | 0.020 |
Why?
|
Cell Shape | 1 | 2013 | 371 | 0.020 |
Why?
|
SOS1 Protein | 1 | 2011 | 40 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 670 | 0.020 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2013 | 426 | 0.020 |
Why?
|
Risk | 1 | 2023 | 9610 | 0.020 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 88 | 0.020 |
Why?
|
raf Kinases | 1 | 2011 | 118 | 0.020 |
Why?
|
Taxoids | 1 | 2014 | 668 | 0.020 |
Why?
|
Materials Testing | 1 | 2015 | 863 | 0.020 |
Why?
|
Base Sequence | 2 | 2013 | 12441 | 0.020 |
Why?
|
Fatigue | 1 | 2018 | 1552 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 624 | 0.020 |
Why?
|
Risk Assessment | 2 | 2013 | 23995 | 0.020 |
Why?
|
Gossypol | 1 | 2010 | 23 | 0.020 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2012 | 255 | 0.020 |
Why?
|
Telomere-Binding Proteins | 1 | 2011 | 119 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2019 | 2385 | 0.020 |
Why?
|
Melanoma, Experimental | 1 | 2014 | 560 | 0.020 |
Why?
|
RNA Splicing | 1 | 2015 | 918 | 0.020 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2011 | 346 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2020 | 2049 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 370 | 0.020 |
Why?
|
Topotecan | 1 | 2010 | 132 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2015 | 1834 | 0.020 |
Why?
|
Cell Aggregation | 1 | 2010 | 239 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1092 | 0.020 |
Why?
|
China | 1 | 2016 | 2369 | 0.020 |
Why?
|
Nitriles | 1 | 2015 | 971 | 0.020 |
Why?
|
Neurofibromin 1 | 1 | 2011 | 190 | 0.020 |
Why?
|
Epithelial Cells | 2 | 2013 | 3673 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2017 | 980 | 0.020 |
Why?
|
Fluorescein Angiography | 1 | 2015 | 1059 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1705 | 0.020 |
Why?
|
Mesoderm | 1 | 2013 | 674 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2015 | 1674 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2015 | 2927 | 0.020 |
Why?
|
Tamoxifen | 1 | 2014 | 965 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2017 | 1403 | 0.020 |
Why?
|
Biomedical Engineering | 1 | 2010 | 288 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 678 | 0.020 |
Why?
|
History, 20th Century | 1 | 2017 | 2767 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2016 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 615 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2013 | 1990 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 1347 | 0.020 |
Why?
|
Antioxidants | 1 | 2017 | 1668 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2645 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2014 | 3597 | 0.020 |
Why?
|
Online Systems | 1 | 2009 | 182 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1646 | 0.020 |
Why?
|
Recurrence | 2 | 2015 | 8465 | 0.020 |
Why?
|
Visual Fields | 1 | 2015 | 1062 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2018 | 2416 | 0.020 |
Why?
|
Pyrroles | 1 | 2014 | 1125 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5035 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1405 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 1115 | 0.020 |
Why?
|
Quinazolinones | 1 | 2010 | 221 | 0.020 |
Why?
|
Temperature | 1 | 2015 | 2226 | 0.020 |
Why?
|
Cell Lineage | 1 | 2017 | 2555 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2850 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2017 | 3208 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3518 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2915 | 0.020 |
Why?
|
Prostate | 1 | 2015 | 1770 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2005 | 5671 | 0.020 |
Why?
|
Massachusetts | 1 | 2019 | 8830 | 0.020 |
Why?
|
Equipment Design | 1 | 2015 | 3510 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 1935 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2013 | 1155 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5789 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 1678 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3606 | 0.020 |
Why?
|
Protein Conformation | 1 | 2013 | 3968 | 0.020 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2008 | 330 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2014 | 1520 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2645 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 1022 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1076 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 629 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2011 | 36426 | 0.010 |
Why?
|
Clinical Laboratory Techniques | 1 | 2010 | 746 | 0.010 |
Why?
|
Health Status | 1 | 2018 | 4077 | 0.010 |
Why?
|
Software | 1 | 2019 | 4434 | 0.010 |
Why?
|
Brain | 1 | 2011 | 27112 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2015 | 2827 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 857 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 21353 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4740 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14414 | 0.010 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2005 | 647 | 0.010 |
Why?
|
Tomography, Optical Coherence | 1 | 2015 | 2917 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13255 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13446 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2011 | 2825 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20098 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17635 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5203 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2010 | 2469 | 0.010 |
Why?
|
Adolescent | 2 | 2020 | 88319 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 3448 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7594 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15936 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26125 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2005 | 4806 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 3530 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 22169 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29874 | 0.010 |
Why?
|
Databases, Factual | 1 | 2009 | 7967 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11528 | 0.010 |
Why?
|
Algorithms | 1 | 2008 | 14031 | 0.000 |
Why?
|